Medical Marijuana, Inc. and AXIM Biotechnologies, Inc. have entered into a strategic alliance to research and develop applications for AXIM's patented water-soluble cannabinoid technology. The collaboration centers on AXIM's U.S. Patent No. 11,542,226 B2, which addresses a fundamental limitation of traditional cannabinoids: their inability to dissolve in water, significantly impairing absorption by the body.
Under the agreement, AXIM assigned Medical Marijuana, Inc. a fifty percent right, title, and economic interest in the patent and all associated intellectual property. This assignment includes rights to existing and future patents, licensing and enforcement proceeds, and claims for past infringement. Medical Marijuana, Inc. paid $600,000 for this interest through a secured promissory note.
Concurrently, the companies entered into a Consulting Agreement where AXIM will provide research and development services focused on developing applications for the patent technology. The agreement has an initial one-year term expiring in January 2027, with Medical Marijuana, Inc. paying AXIM $62,500 per month for these services.
The patented technology represents a significant advancement in cannabinoid delivery. According to the companies, the engineered polyfunctional cannabinoids are more than 300 times more water-soluble than natural cannabinoids, enabling significantly improved absorption and therapeutic delivery. This enhanced solubility could lead to more effective treatments with lower doses, potentially avoiding toxic side effects associated with higher concentrations.
Dr. Timothy R. Scott, who returned as president of Medical Marijuana, Inc. in conjunction with the alliance, expressed confidence in the partnership. "We have tremendous confidence in the AXIM team's ability to provide R&D support for the development of commercialized uses of the Patent technology," Scott stated. "The potential for developing enhanced administration of water soluble CBD and other cannabinoids for certain ailments and conditions is a major development for MJNA."
AXIM President Catalina Valenica highlighted the potential applications of the technology. "The water solubility of CBD and other cannabinoids is a significant development for the improved administration and increased potency of cannabinoids," Valenica said. "We believe that the Patent could result in the development of a drug or treatment, most likely in the form of sublingual administration, able to treat a variety of conditions including anxiety or seizures."
The alliance combines Medical Marijuana, Inc.'s market knowledge and distribution channels with AXIM's technological expertise. Medical Marijuana, Inc. manufactures and distributes hemp-derived CBD products worldwide through subsidiaries including HempMeds® and Kannaway®, which operates as the company's direct selling division. More information about Medical Marijuana, Inc. can be found at https://www.medicalmarijuanainc.com.
This strategic partnership could accelerate the development of new cannabinoid-based treatments, particularly for conditions where traditional oil-based cannabinoids have demonstrated limited bioavailability. The technology's potential for sublingual applications represents a significant advancement in delivery methods that could improve patient outcomes across multiple therapeutic areas.
